Sonic Healthcare Limited (ASX:SHL), one of the world’s larger medical diagnostics groups, is expanding its presence in medical artificial intelligence through software integrations and pathology-focused technology initiatives. While the original article referred to a reported Capital raising involving a medical AI business, that point is based on third-party reporting and has not been verified here from company material, so it has been removed. What can be supported is that Sonic already has visible exposure to AI through Best Practice Software’s clinical tools and through its pathology Partnership with Harrison.ai.

Best Practice adds AI tools to general practice workflows

Best Practice Software has integrated Lyrebird Scribe into Bp Premier, allowing clinicians to generate structured clinical notes, letters and other documentation from consultations within the practice-management system. This is relevant because it shows that Sonic’s broader healthcare ecosystem is extending beyond diagnostics alone and into workflow software used by general practices. Rather than relying only on its laboratory and imaging operations, Sonic is also positioned around tools that can reduce administrative workload and support more efficient clinical documentation.

That makes the medical AI theme more tangible than a single unconfirmed Investment report. The Best Practice-Lyrebird integration is already a live product development, and it suggests that AI-enabled software is becoming part of the wider network surrounding Sonic’s medical services.

Pathology AI remains a clearer strategic fit

Sonic’s more established AI initiative is in pathology. In 2022, Sonic Healthcare and Harrison.ai launched Franklin.ai, a joint venture focused on applying artificial intelligence to pathology workflows. The partnership was presented as a way to develop digital pathology tools that can help pathologists improve efficiency and support diagnostic work. This is a more direct strategic extension of Sonic’s core business, because pathology sits at the centre of the group’s global operations.

The original article also referred to a separate Harrison.ai capital raising figure and broader claims about international use. Those details have been trimmed back here because the more important verified point is the existence of the pathology AI partnership itself. For investors, that partnership matters because it shows Sonic is not treating AI as a peripheral theme; it has already committed to a formal collaboration in an area closely tied to its core diagnostic franchise.

The core Business is funding the digital agenda

Sonic’s AI activity is supported by a large underlying diagnostics business. For the year to 30 June 2026, the company reported Revenue of approximately A$10.867 billion, underlying EBITDA of about A$1.93 billion and net profit of roughly A$621 million. Those figures indicate that Sonic has the scale to support technology investment while continuing to run a broad international pathology and imaging network.

At the same time, the article’s references to a specific three-year AI spending programme and detailed annual technology budgeting have been removed because those points were not verified here from the company material used for this edit. The more reliable conclusion is that Sonic is building AI exposure gradually through existing software and diagnostic platforms rather than through a single transformative announcement.

What investors should watch

For investors, the key issue is not whether Sonic is involved in medical AI, because it clearly is. The more important question is whether these AI-related initiatives become commercially meaningful and clinically embedded over time. In general practice software, success depends on clinician uptake and workflow usefulness. In pathology, it depends on whether AI tools can be integrated safely and productively into routine diagnostic practice.

That means Sonic’s AI strategy should still be viewed as an extension of its broader healthcare services model, rather than a stand-alone investment case. The company remains primarily a diagnostics group, but its software and pathology partnerships show that it is building additional capability in clinical technology that could become more important over time.